Cumulus Neuroscience was formed in 2020 by combining BrainWaveBank with additional new technologies to create the single platform. It was funded by investment from the Dementia Discovery Fund, LifeArc, the UK Futures Fund alongside Brainwavebank’s existing investors.

Six Pharma companies have also contributed and the pharma partnership continues to actively drive the requirements of the platform and are supporting Cumulus’ first study in Alzheimer’s disease starting later this year.

Our platform enables frequent, remote multi-domain sampling outside of the clinic to dramatically improve the robustness of neuroscience clinical trials. These assessments enable more robust and timely decision making in therapeutic development programmes. Our domain assessment technologies have been carefully designed for low patient burden and repeated use, and extensively field-tested by hundreds of users over thousands of hours in patient and control populations.